Thus it should be expected that patients presenting a high number of clonally expanded T cells presenting a high variability of TCRs, meaning high numbers of potentially tumor-specific T cells, should present good responses to ICI as previously found in melanoma and pancreas cancer patients treated with anti CTLA-4 [84,85,86]. This evidence concerns the gene CTLA4 and melanoma.